BRPI0411856A - composições e métodos para o aumento da atividade de telomerase - Google Patents

composições e métodos para o aumento da atividade de telomerase

Info

Publication number
BRPI0411856A
BRPI0411856A BRPI0411856-1A BRPI0411856A BRPI0411856A BR PI0411856 A BRPI0411856 A BR PI0411856A BR PI0411856 A BRPI0411856 A BR PI0411856A BR PI0411856 A BRPI0411856 A BR PI0411856A
Authority
BR
Brazil
Prior art keywords
compositions
methods
telomerase activity
cells
increasing telomerase
Prior art date
Application number
BRPI0411856-1A
Other languages
English (en)
Inventor
Calvin B Harley
Allison C Chin
Tsutomu Akama
Nancy Yuk-Yu Ip
Yung-Hou Wong
David M Miller-Martini
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of BRPI0411856A publication Critical patent/BRPI0411856A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA O AUMENTO DA ATIVIDADE DE TELOMERASE". A presente invenção refere-se a métodos e composições para aumentar a atividade da telomerase em células. Tais composições incluem formulações farmacêuticas, incluindo tópicas, e nutracêuticas. Os métodos e composições são úteis para o tratamento de doenças sujeitas a tratamento por um aumento na atividade de telomerase em células ou tecido de um paciente, tal como, por exemplo, infecção por HIV, diversas doenças degenerativas, e condições agudas ou crónicas da pele. Também são úteis para melhorar a capacidade replicativa de células em cultura como em terapia de célula ex vivo e proliferação de células tronco.
BRPI0411856-1A 2003-06-23 2004-06-23 composições e métodos para o aumento da atividade de telomerase BRPI0411856A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23
PCT/US2004/020277 WO2005000245A2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity

Publications (1)

Publication Number Publication Date
BRPI0411856A true BRPI0411856A (pt) 2006-08-29

Family

ID=33551962

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411856-1A BRPI0411856A (pt) 2003-06-23 2004-06-23 composições e métodos para o aumento da atividade de telomerase

Country Status (24)

Country Link
US (3) US7846904B2 (pt)
EP (2) EP1644009B1 (pt)
JP (4) JP5583882B2 (pt)
KR (3) KR101312389B1 (pt)
CN (1) CN1809364B (pt)
AP (1) AP2280A (pt)
AU (2) AU2004251753C1 (pt)
BR (1) BRPI0411856A (pt)
CA (1) CA2528483C (pt)
CY (2) CY1119951T1 (pt)
DK (2) DK1644009T3 (pt)
EA (1) EA009442B1 (pt)
ES (2) ES2716528T3 (pt)
HR (2) HRP20180330T1 (pt)
HU (2) HUE036559T2 (pt)
LT (2) LT1644009T (pt)
MX (1) MXPA05013844A (pt)
NZ (1) NZ544191A (pt)
PL (2) PL1644009T3 (pt)
PT (2) PT2548880T (pt)
SI (2) SI2548880T1 (pt)
TR (2) TR201802543T4 (pt)
WO (1) WO2005000245A2 (pt)
ZA (1) ZA200509846B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
BRPI0411856A (pt) * 2003-06-23 2006-08-29 Geron Corp composições e métodos para o aumento da atividade de telomerase
WO2005000248A2 (en) * 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (zh) * 2005-09-08 2007-08-29 南京医科大学 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用
CN100384830C (zh) * 2006-01-12 2008-04-30 天津药物研究院 环黄芪醇类衍生物以及用途
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
PL2101789T3 (pl) 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CA2690004C (en) 2007-06-04 2018-01-23 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
CN101225424B (zh) * 2007-09-13 2013-05-29 天津药物研究院 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
WO2010135247A1 (en) * 2009-05-18 2010-11-25 TA Therapeutics, Ltd. Compositions and methods for increasing telomerase activity
CA2912698A1 (en) * 2013-05-15 2014-11-20 Fybrands Corp. Compositions for improving the hair, skin, and nails
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
CN104435370A (zh) * 2014-12-06 2015-03-25 王香平 风湿保健酒
CN104491185A (zh) * 2014-12-06 2015-04-08 郭亮 一种祛风湿药酒及其制备方法
CN104435371A (zh) * 2014-12-06 2015-03-25 郭亮 一种用于治疗关节炎的药酒
KR20160069857A (ko) 2014-12-09 2016-06-17 (주)스피어테크 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법
CN104817610A (zh) * 2015-03-15 2015-08-05 北京化工大学 利用硫酸水解制备环黄芪醇的方法
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN107636149A (zh) 2015-04-03 2018-01-26 普罗帕格尼克斯公司 上皮细胞的离体增殖
CN106474094A (zh) * 2015-08-31 2017-03-08 南京理工大学 一种环黄芪醇电纺纤维膜及其制备方法
EP3892718A1 (en) 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106307522A (zh) * 2016-11-06 2017-01-11 谭淞文 一种抗衰老保健品及其制备方法和食用方法
CN106831927B (zh) * 2017-02-07 2018-02-09 江西师范大学 一种黄芪甲苷的合成方法
CN108498521B (zh) * 2017-02-24 2020-05-05 北京大学 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
US11000537B2 (en) 2018-10-17 2021-05-11 Amorepacific Corporation Composition comprising novel ginsenoside
KR102635196B1 (ko) 2018-10-17 2024-02-13 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 미백 조성물
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
CN109942663B (zh) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 利用双相酸水解制备环黄芪醇的方法
MX2019006749A (es) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Compuestos activadores de senescencia celular.
KR20210037257A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물
KR20210037256A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물
CN111419854B (zh) * 2020-05-18 2021-03-30 南通大学 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用
CN113480628B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种贵州疣螈多肽tk-cath及其编码基因和应用
CN113968894B (zh) * 2021-11-05 2024-05-28 山西大学 一种用黄芪甲苷降解制备环黄芪醇的方法
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212791A (ja) 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン、その単離法およびその用途
JPS6212792A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン類の単離法
IT1259645B (it) 1992-04-10 1996-03-25 Solis Srl Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
FR2695561B1 (fr) 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (ja) * 1994-02-25 1995-09-12 Pola Chem Ind Inc 動脈硬化抑制剤及びこれを含む食品又は医薬
AT402890B (de) 1994-03-16 1997-09-25 Berbi Gmbh Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
RO117328B1 (ro) * 1994-07-07 2002-01-30 Geron Corp Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice
US6162459A (en) 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (zh) 1995-08-01 2002-02-20 裴国增 灵芝口服液及其配制方法
US5785977A (en) 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (ja) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd ジンセノサイド類含有hsp47合成抑制剤
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
EP1783139B8 (en) 1996-10-01 2009-09-23 Geron Corporation Human telomerase catalytic subunit
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
DK0988044T3 (da) 1997-01-28 2008-05-13 Amelio Frank D Vand/ethanol-planteekstrakt af Centipeda cunninghamii
US5786343A (en) 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
WO1999012519A1 (en) 1997-09-05 1999-03-18 The Procter & Gamble Company Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
ATE226064T1 (de) 1997-09-12 2002-11-15 Procter & Gamble Hautreinigungs- und konditionierungsartikel für haut und haar
IL137101A0 (en) 1998-01-12 2001-06-14 Cold Spring Harbor Lab Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
AU5338199A (en) 1998-08-09 2000-02-28 Geron Corporation Methods and compositions for inhibiting or stimulating telomerase assembly
EP1133552A2 (en) 1998-11-25 2001-09-19 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000204091A (ja) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd 新規ベンゾジオキソ―ル誘導体
JP2000229827A (ja) * 1999-02-05 2000-08-22 Kose Corp 皮膚外用剤
JP2000229834A (ja) * 1999-02-10 2000-08-22 Kanebo Ltd 化粧料
AUPQ127399A0 (en) 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
KR100858465B1 (ko) 1999-09-10 2008-09-16 제론 코포레이션 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
JP2001258505A (ja) * 2000-03-24 2001-09-25 Fancl Corp 食品組成物
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
EP1295893A4 (en) 2000-05-31 2005-10-26 Japan Science & Tech Agency GINSENOSIDES FOR PROMOTING SKIN WEBERENEGENERATION
CN1172677C (zh) * 2000-07-14 2004-10-27 复旦大学附属中山医院 黄芪甲苷在制备药物组合物中的应用
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
WO2002007732A2 (en) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
US6696094B2 (en) 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (zh) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 一种抗皮肤过敏的药物组合物及其制法和用途
CN1369276A (zh) 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
WO2002091999A2 (en) 2001-05-09 2002-11-21 Geron Corporation Treatment for wounds
US20020182272A1 (en) 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
WO2003004473A1 (fr) 2001-07-03 2003-01-16 Tanabe Seiyaku Co., Ltd. Nouveaux derives de butadiene, leur procede de preparation et les intermediaires pour leur synthese
JP2003089687A (ja) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd 新規ブタジエン誘導体、その製法およびその合成中間体
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20030108629A1 (en) 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (zh) * 2001-08-31 2004-09-01 上海中医药大学 具有抗心肌纤维化作用的黄芪皂甙甲
CN1406585A (zh) 2001-09-07 2003-04-02 中国科学院上海药物研究所 一种治疗病毒性心肌炎的药物组合物
JP2003160497A (ja) * 2001-11-22 2003-06-03 Toshin Kagaku Kk 皮膚外用剤
AU2003212936A1 (en) 2002-02-04 2003-09-02 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
CN1236803C (zh) 2002-03-20 2006-01-18 郑国芃 一种治疗风湿症的中药
CN1189176C (zh) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 黄芪甲甙组合物及其制备方法
AU2003228378A1 (en) * 2003-03-26 2004-11-23 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
JP2007524616A (ja) * 2003-06-20 2007-08-30 ヴァイラル・ジェノミックス・インコーポレーテッド Hivを処置するための組成物および方法
BRPI0411856A (pt) 2003-06-23 2006-08-29 Geron Corp composições e métodos para o aumento da atividade de telomerase
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
US20070122501A1 (en) 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Also Published As

Publication number Publication date
HRP20190322T1 (hr) 2019-04-19
SI1644009T1 (en) 2018-04-30
KR101312389B1 (ko) 2013-09-27
ES2716528T3 (es) 2019-06-13
EA200600076A1 (ru) 2006-08-25
ES2666864T3 (es) 2018-05-08
HUE036559T2 (hu) 2018-07-30
JP5583882B2 (ja) 2014-09-03
US20110071095A1 (en) 2011-03-24
AP2280A (en) 2011-10-31
HRP20180330T1 (hr) 2018-04-20
EA009442B1 (ru) 2007-12-28
SI2548880T1 (sl) 2019-04-30
EP2548880B1 (en) 2019-01-09
KR20060034237A (ko) 2006-04-21
EP2548880A3 (en) 2013-06-19
WO2005000245A3 (en) 2005-05-26
AU2008249200A1 (en) 2008-12-18
DK2548880T3 (en) 2019-04-08
JP5913253B2 (ja) 2016-04-27
CA2528483A1 (en) 2005-01-06
CA2528483C (en) 2012-04-10
DK1644009T3 (en) 2018-03-05
MXPA05013844A (es) 2006-07-06
NZ544191A (en) 2008-12-24
EP1644009A2 (en) 2006-04-12
AU2004251753C1 (en) 2009-04-09
HUE043168T2 (hu) 2019-08-28
TR201903587T4 (tr) 2019-04-22
KR20130137252A (ko) 2013-12-16
JP2014024861A (ja) 2014-02-06
US8759304B2 (en) 2014-06-24
CN1809364B (zh) 2010-06-16
EP1644009A4 (en) 2010-04-07
PL2548880T3 (pl) 2019-07-31
EP2548880A2 (en) 2013-01-23
AU2004251753A1 (en) 2005-01-06
ZA200509846B (en) 2007-04-25
LT1644009T (lt) 2018-03-12
CY1119951T1 (el) 2018-12-12
JP2016041770A (ja) 2016-03-31
EP1644009B1 (en) 2017-11-29
PT1644009T (pt) 2018-02-28
US20150093455A1 (en) 2015-04-02
CY1121447T1 (el) 2020-05-29
US7846904B2 (en) 2010-12-07
PL1644009T3 (pl) 2018-07-31
US20080113925A1 (en) 2008-05-15
LT2548880T (lt) 2019-03-25
AU2004251753B2 (en) 2008-11-20
KR101465515B1 (ko) 2014-11-26
AP2005003474A0 (en) 2005-12-31
WO2005000245A2 (en) 2005-01-06
CN1809364A (zh) 2006-07-26
JP5841337B2 (ja) 2016-01-13
JP2007524627A (ja) 2007-08-30
JP2011098991A (ja) 2011-05-19
PT2548880T (pt) 2019-02-27
KR20110089887A (ko) 2011-08-09
TR201802543T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
BRPI0411856A (pt) composições e métodos para o aumento da atividade de telomerase
WO2005044179A3 (en) Formulations containing astragalus extracts and uses thereof
AU2015296412B2 (en) Applications of surfactin in cosmetic products and thereof
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
KR20070089907A (ko) 피부 병태, 질환 또는 질병의 치료를 위한 태아 피부 세포단백질 조성물 및 이의 제조 방법 및 이의 사용 방법
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
CN101780031B (zh) 一种用于修复皮肤创面或宫颈粘膜的诱导凝胶
EP2608797A4 (en) CD271 PRECURSOR CELLS FROM BONE MARROW FOR CARDIAC REPAIR
BRPI0418157A (pt) terapêutica de tumores alogênicos
ES2712098T3 (es) Tratamiento de infecciones por VHS con nanofibras de poli-N-acetilglucosamina
Roncati et al. Evaluation of light-emitting diode (led-835 nm) application over human gingival fibroblast: An in vitro study
US20200164014A1 (en) Mesenchymal stem cell attracting agent
BRPI0514030A (pt) derivados de ácido hidroxámico substituìdo por arilssulfonamida, como inibidores de metaloproteinases de matrizes
BR0210994A (pt) Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
BR0208962A (pt) Método para liberar in vivo um oligonucleotìdeo quimérico para dentro de células alvo de um tecido humano ou animal, para tratar uma doença, para obter um modelo animal, para selecionar compostos cosméticos ou farmacêuticos, para tratar um hospedeiro humano possuindo retinopatia e para tratar um hospedeiro humano ou animal possuindo neovascularização ocular, aligonucleotìdeo quimérico, composição farmacêutica, modelo animal, e, uso do mesmo
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
BR0309456A (pt) agentes de proliferação de células
KR101743488B1 (ko) 비피더스균 추출물을 함유하는 지방유래 줄기세포의 줄기세포성 증진용 및 피부세포 증식용 조성물
KR101893339B1 (ko) Gdf11을 포함하는 조성물 및 그의 용도
SG11201900983TA (en) Amelioration and treatment of chronic lung disease using pluripotent stem cells
CN109620859A (zh) 一种疤痕修复软膏及其制备方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL